EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer
Latest Information Update: 03 May 2022
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms EXTEND
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2018 Planned End Date changed from 1 Jul 2018 to 1 Aug 2018.
- 20 Dec 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Feb 2018.